BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Basoglu C, Oner O, Gunes C, Semiz UB, Ates AM, Algul A, Ebrinc S, Cetin M, Ozcan O, Ipcioglu O. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int Clin Psychopharmacol 2010;25:165-71. [PMID: 21811193 DOI: 10.1097/YIC.0b013e3283377850] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Arroyo MB, Kirkpatrick B. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 2017;179:57-63. [PMID: 27743650 DOI: 10.1016/j.schres.2016.09.026] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
2 Huang J, Hei GR, Yang Y, Liu CC, Xiao JM, Long YJ, Peng XJ, Yang Y, Zhao JP, Wu RR. Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients. Front Pharmacol 2020;11:739. [PMID: 32528286 DOI: 10.3389/fphar.2020.00739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Baeza I, Vigo L, de la Serna E, Calvo-Escalona R, Merchán-Naranjo J, Rodríguez-Latorre P, Arango C, Castro-Fornieles J. The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. Eur Child Adolesc Psychiatry 2017;26:35-46. [PMID: 27209421 DOI: 10.1007/s00787-016-0866-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
4 Chang SC, Goh KK, Lu ML. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. World J Psychiatr 2021; 11(10): 696-710 [PMID: 34733637 DOI: 10.5498/wjp.v11.i10.696] [Reference Citation Analysis]
5 Kucukgoncu S, Kosir U, Zhou E, Sullivan E, Srihari VH, Tek C. Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis. Early Interv Psychiatry 2019;13:1021-31. [PMID: 30277314 DOI: 10.1111/eip.12749] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Chen PY, Chang CK, Chen CH, Fang SC, Mondelli V, Chiu CC, Lu ML, Hwang LL, Huang MC. Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome. J Formos Med Assoc 2022:S0929-6646(22)00110-3. [PMID: 35396156 DOI: 10.1016/j.jfma.2022.03.008] [Reference Citation Analysis]
7 Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;211:339-49. [PMID: 28982658 DOI: 10.1192/bjp.bp.117.200907] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
8 Klemettilä JP, Solismaa A, Seppälä N, Hämäläinen M, Moilanen E, Leinonen E, Kampman O. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry Res 2021;306:114227. [PMID: 34610543 DOI: 10.1016/j.psychres.2021.114227] [Reference Citation Analysis]
9 Li S, Zhang R, Hu S, Lai J. Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. Front Psychiatry 2022;13:879414. [DOI: 10.3389/fpsyt.2022.879414] [Reference Citation Analysis]
10 Wysokiński A, Kaźmierski J, Kłoszewska I. Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy. Metab Brain Dis 2015;30:529-35. [PMID: 25034457 DOI: 10.1007/s11011-014-9592-6] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Goh KK, Chen CY, Wu T, Chen C, Lu M. Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. IJMS 2022;23:7092. [DOI: 10.3390/ijms23137092] [Reference Citation Analysis]
12 Chen PY, Chen CH, Chang CK, Kao CF, Lu ML, Lin SK, Huang MC, Hwang LL, Mondelli V. Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. Int J Neuropsychopharmacol 2019;22:28-36. [PMID: 30204875 DOI: 10.1093/ijnp/pyy075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]